Dilution is a way of life for investors in development stage biotechs -- a painful reminder of the costs associated with developing promising new treatments. We have seen a series of high-profile dilutions this month, and in this video health care analyst David Williamson touches on all of them, but focuses in on Aeterna Zentaris action from last week.
Many investors are attracted to Aeterna Zentaris and biotechs like it since they hold the allure of substantial short-term gains. But there is more than one approach to building long-term wealth and retiring well. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.
Dave Williamson has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.